ArticleUltrasonography (Seoul, Korea)2024
Application of O-RADS US combined with MV-Flow to diagnose ovarian-adnexal tumors.
Article in Ultrasonography (Seoul, Korea), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Ultrasound microflow imaging for the evaluation of inflammation associated with superficial vein thrombosis: a proof-of-concept case report.Quantitative imaging in medicine and surgery · 2026Article
- Non-contrast microvascular flow imaging in abdominal ultrasound: a pictorial essay.Journal of ultrasound · 2026Review
- Contrast-enhanced ultrasound and Ovarian-Adnexal Reporting and Data System ultrasound classification for risk assessment of ovarian and adnexal lesions: a systematic review and meta-analysis.Quantitative imaging in medicine and surgery · 2026Article
- A review of ovarian-adnexal reporting and data system and radiomics in ovarian cancer: focus on ultrasound applications.Frontiers in oncology · 2026Review
- Assessment of fetal lung maturity and prediction of neonatal respiratory distress syndrome by MV-Flow imaging.Ultrasonography (Seoul, Korea) · 2025Article
- Exploration of normal placental blood flow characteristics in middle and late pregnancy based on microvascular flow imaging.Pakistan journal of medical sciences · 2025Article
- Efficacy of a combination of O-RADS, CEUS, and CA125, in identification of ovary-adnexal malignant lesions.American journal of cancer research · 2025Article
- Article
- Advanced Visualization of Musculoskeletal Pathologies Using MV-Flow Ultrasound: A Case Series.Cureus · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to explore the application of Ovarian-Adnexal Reporting and Data System Ultrasound (O-RADS US) combined with MV-Flow (Samsung Medison Co., Ltd.) to diagnose ovarian-adnexal masses.
methodsA total of 112 ovarian-adnexal masses (81 benign and 31 malignant) from 105 consecutive patients were analyzed. The O-RADS US and vascular index from MV-Flow (VIMV) were measured and compared with the reference standard. O-RADS US and MV-Flow were tested for consistency.
resultsReceiver operating characteristic curves were drawn for O-RADS US, MV-Flow, and their combination. The combined methods had the largest area under the curve (0.955), followed by O-RADS US (0.929) and MV-Flow (0.923). A mass was considered malignant when the O-RADS US classification was 5 and VIMV was ≥7.15. With this definition, MV-Flow had the highest sensitivity (87.10%), with consistent findings for the combined diagnostic methods and O-RADS US (83.87%). The specificity of the combined diagnostic methods (93.83%) was higher than that of MV-Flow (91.36%). O-RADS US had the lowest specificity (90.12%). The combined diagnostic methods had the highest coincidence rate (91.07%), and MV-Flow (90.18%) had a significantly higher coincidence rate than O-RADS US (88.39%). Both O-RADS US and MV-Flow showed good consistency among different physicians (former kappa, 0.974; latter intraclass correlation coefficient [ICC], 0.986). MV-Flow had a high consistency for the same physician (ICC, 1).
conclusionO-RADS US and MV-Flow exhibited good diagnostic efficacy, and their combined diagnostic efficacy was higher than that of each individually. O-RADS US and MV-Flow can improve the diagnosis of benign and malignant ovarian-adnexal masses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.